Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Shares Traded Last Trade
  10.50 0.89% 1,184.00 144,721 09:52:41
Bid Price Offer Price High Price Low Price Open Price
1,183.50 1,184.50 1,185.50 1,177.00 1,179.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,854.13 433.33 44.22 23.9 10,330
Last Trade Time Trade Type Trade Size Trade Price Currency
09:52:41 AT 737 1,184.00 GBX

Smith & Nephew (SN.) Latest News

More Smith & Nephew News
Smith & Nephew Investors    Smith & Nephew Takeover Rumours

Smith & Nephew (SN.) Discussions and Chat

Smith & Nephew Forums and Chat

Date Time Title Posts
05/1/202312:20*** Smith and Nephew ***597
29/10/201508:48SN.122
10/1/201113:03Smith and Nephew 200867
09/1/201117:12Smiths: Charts and News etc.296
25/9/200614:09Smith&Nep. Why the rise?75

Add a New Thread

Smith & Nephew (SN.) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09:52:411,184.007378,726.08AT
09:52:411,184.005256,216.00AT
09:52:401,184.502402,842.80AT
09:51:431,184.244455,269.87O
09:51:041,184.761501,777.14O
View all Smith & Nephew trades in real-time

Smith & Nephew (SN.) Top Chat Posts

Top Posts
Posted at 08/2/2023 08:20 by Smith & Nephew Daily Update
Smith & Nephew Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker SN.. The last closing price for Smith & Nephew was 1,173.50p.
Smith & Nephew Plc has a 4 week average price of 1,103p and a 12 week average price of 1,046p.
The 1 year high share price is 1,344p while the 1 year low share price is currently 959.20p.
There are currently 872,505,009 shares in issue and the average daily traded volume is 2,460,225 shares. The market capitalisation of Smith & Nephew Plc is £10,326,096,781.52.
Posted at 07/12/2022 15:38 by suetballs
https://www.telegraph.co.uk/news/2022/12/05/faulty-knee-replacements-given-10000-patients/
Glad this wasn't sn.
Suet

Posted at 04/11/2022 17:32 by cerrito
As a SN. holder I listened to most of the recording of yesterday's webcast.
Alot of good stuff especially in logistics and optimization of inventory and US improvement but what stopped me pushing the buy button was not so much the supply shortages(especially semi conductors and resins) but rather that in the Q&A the difficulty they were having on passing on cost increases came up 2/3 times.

Posted at 03/11/2022 10:19 by disc0dave45
Seem to be following the same stocks!From the healthcare sector I've got SN on my watchlist and good to see they are in line. Some of the constraining factors (materials and staff shortages, FX headwinds) could develop into major issues but who knows.
Posted at 06/9/2022 07:48 by roguetraderuk
unless share price were to move up 10% or more then v v unlikely any rns. in any case i think its a passive stake build. any offer is likely going to have to be over 15/16 quid here and its not a level the board will accept at this point. next year i think that that price will be more acceptable. not necessarily because the share price will be much lower at that time (i dont think they go much below 10 maybe to 950 but if they do then 8 is quite prob in that case) but the longer the share price is lower than the more pressure the board will be under to accept a price around 15/16. personally think its still a lot of money to pay inc of all debt so its only the americans that could be interested.
Posted at 25/8/2022 10:56 by 1bearbull
It cannot help in terms of investor confidence when in his first major public appearance he announces a profits warning and if I remember correctly the share fell by 10%.
Posted at 25/8/2022 10:51 by 1bearbull
It is difficult to get excited when a Company has a CEO without any shareholding. Moreover, he can take up to 5 years or so to buy some. What is his incentive to get the share price up?
Posted at 30/7/2022 17:24 by berny3
in light of the price drop after earnings. The transcript of the earnings call is in the below link and also a recording of the call. personally I think the price drop is over done. In particular it is worth listening to the questions at the end. focus was made on this and i think good answers were given. www.seekingalpha.com/article/4527703-smith-and-nephew-plc-snn-ceo-deepak-nath-on-q2-2022-results-earnings-call-transcript
Posted at 28/7/2022 14:03 by justiceforthemany
EI that CEO sale was apparently forced - see IR response

The sales that were reported immediately followed receipt of a share award, that was made as part of buying out outstanding share awards from Deepak Nath's former company, that he had to forfeit upon leaving that company to join Smith+Nephew. It does not relate to any business developments.

Looking forward, the Chief Executive Officer is required to hold three times his salary in the form of shares, with a time of five years from his appointment to meet that requirement.

Posted at 28/7/2022 12:44 by essentialinvestor
£13/4 bn to take this out - plus their £2 bn approx in net debt.


Is SN. worth £15 bn...looks a stretch to me but never say never.


Stryker already carry a lump of debt, realistically only leaves JnJ imv.

Posted at 17/12/2021 14:13 by roguetraderuk
some advice re sn. the share price will begin to outperform when the mkt believes elected surgery for sn. has turned the corner. it will likely go mkt perform as others start giving signals (stryker, medtronic, intuitive etc) but as i say the big outperformance will come when the company points to a return to trend growth. demand issue and supply chains issues all due to covid and the variants are extending the point of turn in trend. i think it should reach equilibrium by q2 2022, i suspect the shares will bottom by then if not sooner. it all depends on the news and if its leaked and other news from others in the area. i dont think they will get too much cheaper as i would expect the americans to start sniffing. there is plenty to put right at sn. but that means a large upside for any buyer. personally i think they will stay independant until jnj do their split and the jnj arm likely picks up sn. but we will see. if they get cheap enough (10 quid or lower) someone may step up earlier. given that they are likely to underperfrom their peers next year, i wouldnt expect outperformance from here now, but of course i cant see the future and a bid would change all that.
Smith & Nephew share price data is direct from the London Stock Exchange
Your Recent History
LSE
SN.
Smith & Ne..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230208 10:08:49